Todd A Pezzi1, Abdallah S R Mohamed2,3, Tommy Sheu2, Pierre Blanchard2, Vlad C Sandulache4, Stephen Y Lai5, Maria E Cabanillas6, Michelle D Williams7, Christopher M Pezzi8, Charles Lu9, Adam S Garden2, William H Morrison2, David I Rosenthal2, Clifton D Fuller2, G Brandon Gunn2. 1. Baylor College of Medicine, Houston, Texas. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 4. Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. 5. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Surgery, Abington Hospital-Jefferson Health, Abington, Pennsylvania. 9. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The outcomes of patients with unresected anaplastic thyroid carcinoma (ATC) from the National Cancer Data Base (NCDB) were assessed, and potential correlations were explored between radiation therapy (RT) dose and overall survival (OS). METHODS: The study cohort was comprised of patients who underwent either no surgery or grossly incomplete resection. Correlates of OS were explored using univariate analysis and multivariable analysis (MVA). RESULTS: In total, 1288 patients were analyzed. The mean patient age was 70.2 years, 59.7% of patients were women, and 47.6% received neck RT. The median OS was 2.27 months, and 11% of patients remained alive at 1 year. A positive RT dose-survival correlation was observed for the entire study cohort, for those who received systemic therapy, and for those with stage IVA/IVB and IVC disease. On MVA, older age (hazard ratio [HR], 1.317; 95% confidence interval [CI], 1.137-1.526), ≥ 1 comorbidity (HR, 1.587; 95% CI, 1.379-1.827), distant metastasis (HR, 1.385; 95% CI, 1.216-1.578), receipt of systemic therapy (HR, 0.637; 95% CI, 0.547-0.742), and receipt of RT compared with no RT (<45 grays [Gy]:HR, 0.843; 95% CI, 0.718-0.988; 45-59.9 Gy: HR, 0.596; 95% CI, 0.479-0.743; 60-75 Gy: HR, 0.419; 95% CI, 0.339-0.517) correlated with OS. The RT dose-survival correlation for patients who received higher (60-75 Gy) versus lower (45-59.9 Gy) therapeutic doses was confirmed by propensity-score matching. CONCLUSIONS: Survival was poor in this cohort of patients with unresected ATC, and more effective therapies are needed. However, the association of RT dose with OS highlights the importance of identifying patients with unresected ATC who may still yet benefit from multimodal locoregional treatment that incorporates higher dose RT. Cancer 2017;123:1653-1661.
BACKGROUND: The outcomes of patients with unresected anaplastic thyroid carcinoma (ATC) from the National Cancer Data Base (NCDB) were assessed, and potential correlations were explored between radiation therapy (RT) dose and overall survival (OS). METHODS: The study cohort was comprised of patients who underwent either no surgery or grossly incomplete resection. Correlates of OS were explored using univariate analysis and multivariable analysis (MVA). RESULTS: In total, 1288 patients were analyzed. The mean patient age was 70.2 years, 59.7% of patients were women, and 47.6% received neck RT. The median OS was 2.27 months, and 11% of patients remained alive at 1 year. A positive RT dose-survival correlation was observed for the entire study cohort, for those who received systemic therapy, and for those with stage IVA/IVB and IVC disease. On MVA, older age (hazard ratio [HR], 1.317; 95% confidence interval [CI], 1.137-1.526), ≥ 1 comorbidity (HR, 1.587; 95% CI, 1.379-1.827), distant metastasis (HR, 1.385; 95% CI, 1.216-1.578), receipt of systemic therapy (HR, 0.637; 95% CI, 0.547-0.742), and receipt of RT compared with no RT (<45 grays [Gy]:HR, 0.843; 95% CI, 0.718-0.988; 45-59.9 Gy: HR, 0.596; 95% CI, 0.479-0.743; 60-75 Gy: HR, 0.419; 95% CI, 0.339-0.517) correlated with OS. The RT dose-survival correlation for patients who received higher (60-75 Gy) versus lower (45-59.9 Gy) therapeutic doses was confirmed by propensity-score matching. CONCLUSIONS: Survival was poor in this cohort of patients with unresected ATC, and more effective therapies are needed. However, the association of RT dose with OS highlights the importance of identifying patients with unresected ATC who may still yet benefit from multimodal locoregional treatment that incorporates higher dose RT. Cancer 2017;123:1653-1661.
Authors: Aarti Bhatia; Archana Rao; Kie-Kian Ang; Adam S Garden; William H Morrison; David I Rosenthal; Douglas B Evans; Gary Clayman; Steven I Sherman; David L Schwartz Journal: Head Neck Date: 2010-07 Impact factor: 3.147
Authors: Eric J Sherman; Su Hsien Lim; Alan L Ho; Ronald A Ghossein; Matthew G Fury; Ashok R Shaha; Michael Rivera; Oscar Lin; Suzanne Wolden; Nancy Y Lee; David G Pfister Journal: Radiother Oncol Date: 2011-10-06 Impact factor: 6.280
Authors: Nikola Besic; Marko Hocevar; Janez Zgajnar; Ana Pogacnik; Snjezana Grazio-Frkovic; Marija Auersperg Journal: Langenbecks Arch Surg Date: 2004-12-15 Impact factor: 3.445
Authors: Todd A Pezzi; Vlad C Sandulache; Christopher M Pezzi; Ashley E Turkeltaub; Lei Feng; Maria E Cabanillas; Michelle D Williams; Stephen Y Lai Journal: Head Neck Date: 2016-02-04 Impact factor: 3.147
Authors: E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila Journal: Clin Transl Oncol Date: 2020-01-31 Impact factor: 3.405
Authors: Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins Journal: Head Neck Date: 2019-12-16 Impact factor: 3.147
Authors: Dan Fan; Jennifer Ma; Andrew C Bell; Andries H Groen; Kyrie S Olsen; Benjamin H Lok; Jonathan E Leeman; Erik Anderson; Nadeem Riaz; Sean McBride; Ian Ganly; Ashok R Shaha; Eric J Sherman; C Jillian Tsai; Jung J Kang; Nancy Y Lee Journal: Cancer Date: 2019-10-08 Impact factor: 6.860
Authors: Ayman Oweida; Andy Phan; Benjamin Vancourt; Tyler Robin; Mohammad K Hararah; Shilpa Bhatia; Dallin Milner; Shelby Lennon; Laura Pike; David Raben; Bryan Haugen; Nikita Pozdeyev; Rebecca Schweppe; Sana D Karam Journal: Thyroid Date: 2018-06 Impact factor: 6.568
Authors: Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark Journal: Thyroid Date: 2021-03 Impact factor: 6.568